The global epigenetics diagnostic market size is estimated to expand at a substantial CAGR during the forecast period, 2021 – 2028. The growth of the market is attributed to the rising prevalence of cancer and other chronic diseases, which is accelerated due to the increasing geriatric population.
Request Free Sample Report Here
Epigenetics is a part of the analysis of hereditary changes of gene expression; which means a characteristic shift is occurred without a change of genotype. Epigenetic alteration is a common and natural process, which is mainly influenced by a number of factors such as aging, climate or lifestyle, and disease state. Several continuing research continue to shed light on the role of epigenetics in a wide range of human illnesses and fatal diseases including cancer, heart disease, diabetes, and mental illnesses. Epigenetic treatment can be used to specifically affect certain pathways. Epigenetic medications and diagnostics, as well as other abnormal alterations of skin cells, liver cells, brain cells, and others, are used in early-stage cancer screening.
Epigenetic test kits are also used to detect diseases caused by early-stage epigenetic modifications to validate drug effectiveness during treatment. Centered on immunoprecipitation, they act by using modification-specific monoclonal antibodies. Epigenetic drugs are types of medicine widely adopted to cure various types of cancers as well as other diseases such as respiratory diseases and Alzheimer's disease. These drugs are divided into two categories: DNA methylation inhibitors and histone deacetylase inhibitors. The US Food and Drug Administration (FDA) has approved several cancer treatment medications to improve their treatment using chemotherapy sensitization, radiotherapy, and immune system modulation.
Market Trends, Drivers, Restraints, and Opportunities
- Rising prevalence of chronic illness and diseases related to hereditary or genotype of patients are key factors boosting the market growth.
- Extensive funding for research and product development under the initiatives of major organizations such as the International Human Epigenome Consortium (IHEC), the National Cancer Institute (NCI), and the National Institutes of Health (NIH) are expected to drive market growth.
- Rapid development of advanced healthcare facilities and diagnostic clinics to provide effective solution for epigenetics testing and offer reliable therapeutics solutions present major drivers for the market.
- Lack of experts or technicians handling the diagnostic process and lack of advanced medical facilities in developing countries act as key challenges that can hamper the market growth.
- Extensive R&D activities and wide adoption of innovative technology in the testing devices for epigenetics diagnostic are expected to create lucrative opportunities for the market players.
Market Segment Insights
Reagents segment to hold a key market share
Based on products, the global epigenetics diagnostic market is divided into reagents, kits, instruments, enzymes, and services. The kits segment is further divided into ChIP sequencing kit, whole genomic amplification kit, bisulfite conversion kit, RNA sequencing kit, and others. The reagents segment is anticipated to account for a key share of the market during the forecast period owing to wide adoption of the several reagents employed in the diagnostics.
DNA methylation segment to constitute a major market share
On the basis of technology, the market is divided into DNA methylation, histone methylation, histone acetylation, large non-coding RNA, microRNA modification, and chromatin structures. The DNA methylation segment is projected to constitute a major market share in the coming years owing to wide adoption of the technology. Methylation sensitive PCR refers to the process of sensitive bi-sulphite modification accompanied by PCR (MSP) and is the covalent addition of a methyl group to the cytosine ring that causes transcription to be inhibited.
Oncology segment is likely to dominate the market
Based on applications, the global global epigenetics diagnostic market is divided into oncology and non-oncology. The oncology segment is further bifurcated into solid tumors and liquid tumors; while, the non-oncology segment consists of inflammatory diseases, metabolic diseases, infectious diseases, cardiovascular diseases, and others.
North America to exhibit a high CAGR
In terms of regions, the market is divided into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to exhibit a high CAGR during the forecast period owing to the presence of advanced technological facilities, successful campaigns, and constantly increasing geriatric population in the region.
Compititive Landscape
Roche Diagnostics, Thermo Fisher Scientific, Inc., Eisai Co. Ltd., and Novartis AG are key players competing in the market. To grow their market share, major players are concentrating on expanding their companies in emerging regions. Furthermore, they are implementing policies such as mergers and acquisitions, as well as the development of new technologies to enhance their market position.
About Growth Market Reports:
GROWTH MARKET REPORTS provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. GROWTH MARKET REPORTS has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.
Contact:
Growth Market Reports
Phone: +1 909 414 1393
Email: [email protected]
Web: https://growthmarketreports.com
Epigenetics Drugs and Diagnostic Technologies Market is valued at USD 7.71 Billion in 2018 and expected to reach USD 27.13 Billion by 2025 with the CAGR of 19.68% over the forecast period.Growing prevalence of oncological and non-oncological conditions like respiratory diseases, alzheimer disease and growing R & D investments in the healthcare industries promotes the growth of global epigenetics drugs and diagnostic technologies market.
Epigenetic change is a normal and natural phenomenon but can also be affected by a variety of factors like age, environment or lifestyle and disease state.
New and ongoing work continues to uncover the role of epigenetics in a variety of human disorders and fatal diseases.
Epigenetic drugs and diagnostics are used in early stage cancer screening, as well as other pathological modifications in skin cells, liver cells, brain cells and others.
On the basis of country level, global Epigenetics Drugs and Diagnostic Technologies Market sub divided in U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.Epigenetics Drugs and Diagnostic Technologies CompaniesGlobal Epigenetics Drugs and Diagnostic Technologies Market reports cover prominent players,Zymo researchCellCentric LtdThermo Fisher ScientificAbcam, Eisai Co. LtdDiagenodeMerckElli LillySyndax Pharmaceuticals, Inc.QiagenChroma Therapeutics LtdNovartis International AGOncolys Biopharma IncSigma-Aldrich CorporationValirx Plcothers.
Cancer is a leading cause of death for children and adolescents worldwide and about 300,000 children aged 0 to 19 are diagnosed with cancer every year.
